- VTv Therapeutics' (NASDAQ:VTVT) two late-breaking abstracts reinforcing the potential of TTP399 as an oral adjunctive therapy in type 1 diabetes will be presented at the American Diabetes Association’s 80th Scientific Sessions, which is being held virtually, June 12–16, 2020.
- Details of the virtual presentations which will provide full clinical study data from that trial are as follows:
- Poster I Title: “The Simplici-T1 Trial: Glucokinase Activator TTP399 Improves Glycemic Control in Patients with Type 1 Diabetes”, and;
- Poster II Title: “The Simplici-T1 Trial: Relationship between Glycemic Control and Insulin Dose”.
- Shares are up 8% premarket.